FY2026 EPS Estimates for Homology Medicines, Inc. Reduced by HC Wainwright (NASDAQ:FIXX)

Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) – Analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Homology Medicines in a research note issued on Thursday, March 16th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.17 per share for the year, down from their prior forecast of $0.28. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Homology Medicines’ current full-year earnings is ($2.00) per share.

Homology Medicines Price Performance

Shares of NASDAQ FIXX opened at $0.95 on Friday. The company has a market capitalization of $54.80 million, a price-to-earnings ratio of -8.64 and a beta of -0.01. The business has a 50-day moving average of $1.47 and a two-hundred day moving average of $1.54. Homology Medicines has a 1 year low of $0.95 and a 1 year high of $3.57.

Institutional Trading of Homology Medicines

A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP lifted its holdings in Homology Medicines by 40.4% during the 3rd quarter. Marshall Wace LLP now owns 30,175 shares of the company’s stock worth $48,000 after buying an additional 8,689 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Homology Medicines by 6.3% during the 2nd quarter. Renaissance Technologies LLC now owns 248,800 shares of the company’s stock worth $490,000 after buying an additional 14,800 shares during the last quarter. Bank of America Corp DE lifted its holdings in Homology Medicines by 4.5% during the 4th quarter. Bank of America Corp DE now owns 361,621 shares of the company’s stock worth $456,000 after buying an additional 15,467 shares during the last quarter. Raymond James & Associates acquired a new stake in shares of Homology Medicines during the first quarter worth about $51,000. Finally, Mirabella Financial Services LLP acquired a new stake in shares of Homology Medicines during the first quarter worth about $53,000. 40.73% of the stock is owned by hedge funds and other institutional investors.

About Homology Medicines

(Get Rating)

Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.